PIA
AKBA icon

Piedmont Investment Advisors’s Akebia Therapeutics AKBA Stock Holding History

Piedmont Investment Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-875
Closed -$9K – 1079
2018
Q2 		$9K Buy
+875
New +$8.76K ﹤0.01% 1854

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Piedmont Investment Advisors's AKBA Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Akebia Therapeutics (AKBA) in Q3 2018, closing a stake of 875 shares — an estimated $9K sold.

Piedmont Investment Advisors first reported a position in AKBA in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 130 funds tracked by Wall St. Rank hold AKBA as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Akebia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 875 Akebia Therapeutics shares in Q3 2018, an estimated $9K.
  • Piedmont Investment Advisors first reported a position in Akebia Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Akebia Therapeutics position peaked at $9K in Q2 2018.
  • 130 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.